Michele F. Mercuri

Michele F. Mercuri, MD, PhD, FAHA, FESC, is a physician scientist professionally devoted to fostering the discovery, research, translation and development of innovative diagnostic, prophylactic, and therapeutic medical tools. Currently, Dr. Mercuri leads the Global Amyloidosis, Rare Cardiac and Metabolic Diseases Therapeutic Area at Alexion Pharmaceuticals, AstraZeneca Rare Disease. Dr. Mercuri is an adjunct Professor, Biomedical Engineering and Imaging Institute, Mount Sinai, and serves as a member of the Scientific Advisory Board for Pe-dosphere Tech.

Dr. Mercuri graduated in medicine and surgery from the University of Perugia (Italy), and trained in Internal and Geriatric Medicine at the Universities of Parma (Italy) and Modena (Italy).

A fellow in Cerebrovascular Disease and Vascular Ultrasound at the Bowman Gray School of Medicine at Wake Forest University (Winston-Salem, NC, USA), Dr. Mercuri served on the Medical School Faculty and as the Co-Director of the Division of Vascular Ultrasound. Dr. Mercuri joined the Pharmaceutical Industry with Merck Research Laboratory (Rahway, NJ, USA) in 1996 and worked on a wide range of cardiometabolic drugs in all phases of research and development.

In 2003, Dr. Mercuri moved to Novartis Pharmaceuticals’ Clinical Development & Medical Affairs (East Hanover, NJ, USA) to lead Cardiometabolic Disease and Atherosclerosis drug development prior to assuming leading positions within the Methodology and Innovation Global Development group, and in the Division of Haematology and Oncology. Prior to joining Alexion in 2018, Dr. Mercuri spent 10 years at Daiichi Sankyo leading the development of edoxaban—an oral, direct factor Xa inhibitor.

Dr. Mercuri served as the Global Head for cardio, vascular, metabolic and renal disease Therapeutic Area for translational sciences and clinical development, Chief Medical Advisor to the Head of Development, and Head of Clinical Development for the Americas. Dr. Mercuri published over 100 articles in peer-reviewed medical and scientific journals in collaboration with leading scientists from around the world.